JP2022553862A - 活性剤投与用胃内滞留型システム - Google Patents

活性剤投与用胃内滞留型システム Download PDF

Info

Publication number
JP2022553862A
JP2022553862A JP2022526215A JP2022526215A JP2022553862A JP 2022553862 A JP2022553862 A JP 2022553862A JP 2022526215 A JP2022526215 A JP 2022526215A JP 2022526215 A JP2022526215 A JP 2022526215A JP 2022553862 A JP2022553862 A JP 2022553862A
Authority
JP
Japan
Prior art keywords
gastric retention
retention system
arm
linker
plga
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022526215A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022553862A5 (https=
Inventor
カナスティー ローズマリー
グラント タイラー
オルトルーター デイビッド
ウェイト アリシャ
ムアシー ソームヤ
タイ タミー
ジャラミロ モンテスコ ジュアン
シュワルツ マーリーン
フン ヤン チュン
トラン ジーン
ドゥアン ミッシェル
チン チエ
シー．デュフォア デイビッド
ロバート ワルデマー ライド エリック
ビース ヌプラ
デ ラ トール ニコラス
ホラー ソニア
ベギン エステレ
シムセス クレイグ
ピーク エリック
レイ エリカ
Original Assignee
リンドラ セラピューティクス， インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by リンドラ セラピューティクス， インコーポレイティド filed Critical リンドラ セラピューティクス， インコーポレイティド
Publication of JP2022553862A publication Critical patent/JP2022553862A/ja
Publication of JP2022553862A5 publication Critical patent/JP2022553862A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022526215A 2019-11-08 2020-11-06 活性剤投与用胃内滞留型システム Pending JP2022553862A (ja)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US201962933211P 2019-11-08 2019-11-08
US201962933210P 2019-11-08 2019-11-08
US201962933348P 2019-11-08 2019-11-08
US201962933313P 2019-11-08 2019-11-08
US201962933226P 2019-11-08 2019-11-08
US62/933,210 2019-11-08
US62/933,348 2019-11-08
US62/933,211 2019-11-08
US62/933,226 2019-11-08
US62/933,313 2019-11-08
US202062992075P 2020-03-19 2020-03-19
US62/992,075 2020-03-19
US202063052905P 2020-07-16 2020-07-16
US63/052,905 2020-07-16
PCT/US2020/059541 WO2021092491A1 (en) 2019-11-08 2020-11-06 Gastric residence systems for administration of active agents

Publications (2)

Publication Number Publication Date
JP2022553862A true JP2022553862A (ja) 2022-12-26
JP2022553862A5 JP2022553862A5 (https=) 2023-11-14

Family

ID=75849597

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022526215A Pending JP2022553862A (ja) 2019-11-08 2020-11-06 活性剤投与用胃内滞留型システム

Country Status (10)

Country Link
US (1) US20220387311A1 (https=)
EP (1) EP4054545A4 (https=)
JP (1) JP2022553862A (https=)
CN (1) CN115003335A (https=)
AU (1) AU2020378438A1 (https=)
BR (1) BR112022008908A2 (https=)
CA (1) CA3160665A1 (https=)
IL (1) IL292849A (https=)
MX (1) MX2022005494A (https=)
WO (1) WO2021092491A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020117855A1 (en) 2018-12-03 2020-06-11 Lyndra, Inc. Stomach simulating device
AU2020242062B2 (en) 2019-03-20 2025-12-11 Nortiva Bio, Inc. Coatings for gastric residence dosage forms
BR112021018496A2 (pt) 2019-03-20 2021-11-30 Lyndra Therapeutics Inc Cápsulas e revestimento de cápsula para formas de dosagem de residência gástrica
JP7847119B2 (ja) 2020-07-29 2026-04-16 ザ・セカント・グループ・エルエルシー 架橋ポリ（セバシン酸グリセロール）を含む構造を含む形状誘導型制御放出および保持
US20240390270A1 (en) * 2021-01-19 2024-11-28 Lyndra Therapeutics, Inc. Gastric residence systems for administration of risperidone
AU2023209872A1 (en) * 2022-01-19 2024-08-01 Nortiva Bio, Inc. Dosage forms for gastric retention
CN115227879B (zh) * 2022-09-15 2023-01-06 北京天星博迈迪医疗器械有限公司 一种用于可降解关节球囊的组合物及其应用、一种可降解关节球囊及其制备方法
US20240398701A1 (en) * 2023-06-02 2024-12-05 Lyndra Therapeutics, Inc. Manufacturing methods for gastric residence systems
WO2025042349A1 (en) * 2023-08-24 2025-02-27 Junion Therapeutics (Xiamen) Co., Ltd. A gastric residence article for oral administration
CN121752250A (zh) * 2023-08-24 2026-03-27 厦门君德医药科技有限公司 一种口服胃滞留物
WO2025148850A1 (zh) * 2024-01-09 2025-07-17 厦门君德医药科技有限公司 一种胃滞留装置
WO2025153071A1 (en) * 2024-01-18 2025-07-24 Junion Therapeutics (Xiamen) Co., Ltd. Gastric residence article for oral administration
WO2025195482A1 (zh) * 2024-03-22 2025-09-25 厦门君德医药科技有限公司 一种胃滞留装置

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018064630A1 (en) * 2016-09-30 2018-04-05 Lyndra, Inc. Gastric residence systems for sustained delivery of adamantane-class drugs
JP2019503347A (ja) * 2015-12-08 2019-02-07 リンドラ，インコーポレイティド 胃滞留システムのための幾何学的構成
JP2022526233A (ja) * 2019-03-25 2022-05-24 ダグラス ファーマシューティカルズ エルティーディー． 持続放出性の医薬製剤

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9925962D0 (en) * 1999-11-02 1999-12-29 Novartis Ag Organic compounds
WO2007084460A2 (en) * 2006-01-18 2007-07-26 Qps, Llc Pharmaceutical compositions with enhanced stability
US9622966B2 (en) * 2007-07-06 2017-04-18 Basf Corporation Gastroretentive composition on the basis of a water-soluble reaction product from a vinyl group-containing precursor
WO2011124953A2 (en) * 2010-04-07 2011-10-13 Lupin Limited Controlled release pharmaceutical compositions of tapentadol
AU2011285554C1 (en) * 2010-08-06 2016-05-12 Endoshape, Inc. Radiopaque shape memory polymers for medical devices
NZ727659A (en) * 2014-06-11 2021-12-24 Massachusetts Inst Technology Residence structures and related methods
US11576859B2 (en) * 2015-10-23 2023-02-14 Lyndra Therapeutics, Inc. Gastric residence systems for sustained release of therapeutic agents and methods of use thereof
CN109310639A (zh) * 2016-05-27 2019-02-05 林德拉有限公司 用于胃驻留系统的材料结构
CA3066658A1 (en) * 2017-06-09 2018-12-13 Lyndra, Inc. Gastric residence systems with release rate-modulating films
US11793751B2 (en) * 2017-09-20 2023-10-24 Lyndra Therapeutics, Inc. Encapsulation of gastric residence systems

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019503347A (ja) * 2015-12-08 2019-02-07 リンドラ，インコーポレイティド 胃滞留システムのための幾何学的構成
WO2018064630A1 (en) * 2016-09-30 2018-04-05 Lyndra, Inc. Gastric residence systems for sustained delivery of adamantane-class drugs
JP2022526233A (ja) * 2019-03-25 2022-05-24 ダグラス ファーマシューティカルズ エルティーディー． 持続放出性の医薬製剤

Also Published As

Publication number Publication date
AU2020378438A1 (en) 2022-06-02
WO2021092491A1 (en) 2021-05-14
US20220387311A1 (en) 2022-12-08
EP4054545A1 (en) 2022-09-14
IL292849A (en) 2022-07-01
CA3160665A1 (en) 2021-05-14
MX2022005494A (es) 2022-08-11
CN115003335A (zh) 2022-09-02
BR112022008908A2 (pt) 2022-10-11
EP4054545A4 (en) 2024-02-14

Similar Documents

Publication Publication Date Title
JP2022553862A (ja) 活性剤投与用胃内滞留型システム
US20240342081A1 (en) Geometric configurations for gastric residence systems
US20220409528A1 (en) Gastric residence systems having a filament for improved gastric residence
JP2022116316A (ja) 治療薬の持続放出用の胃内滞留システム及びその使用方法
US20230190941A1 (en) Polymeric linkers for a gastric residence system
JP2022554383A (ja) 胃内滞留システムのための放出速度調節フィルム用製剤
JP2024503485A (ja) リスペリドンを投与するための胃内滞留システム
US20220387312A1 (en) Gastric residence systems having arms with controlled stiffness for improved gastric residence
US20240398701A1 (en) Manufacturing methods for gastric residence systems
AU2020378100B2 (en) Polymeric linkers for a gastric residence system
TWI837082B (zh) 用於胃滯留系統之材料架構
US20250295901A1 (en) Flexible line configurations for gastric residence systems
RU2806007C2 (ru) Геометрические компоновки систем длительного нахождения в желудке
HK40106006A (en) Geometric configurations for gastric residence systems
TW202500122A (zh) 用於胃滯留系統之材料架構

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231106

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231106

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250204

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250603

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250901

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251202

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260331

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20260422